Mind + Muscle

technical minds + legal muscle


dig deep

Caraco v. Novo Nordisk (PrandinĀ®): Federal Circuit Reversed in Patent Use Code Case

  • 04.18.12
  • Sterne, Kessler, Goldstein & Fox

On April 17, 2012, the U.S. Supreme Court issued a unanimous decision delivered by Justice Kagan in Caraco Pharmaceutical Laboratories Ltd. v. Novo Nordisk A/S, reversing the Federal Circuit and holding that a generic manufacturer (Caraco) may force correction of an Orange Book use code that inaccurately describes a brand company's (Novo's) patent as covering a particular method of using the drug in question under 21 U.S.C. §355(j)(5)(C)(ii)(I) ("the counterclaim provision"). To read the full summary, download the attached PDF.

Related People

Related Industries

Sort By Media Type

Sort By Media Type
  • AlertAlert
  • BriefsBriefs
  • Comments to USPTOComments to USPTO
  • Design Patent Case DigestDesign Patent Case Digest
  • MultimediaMultimedia
  • News & ArticlesNews & Articles
  • Press ReleasePress Release
  • VideoVideo
  • WebinarWebinar

Unsolicited e-mails and information sent to Sterne, Kessler, Goldstein & Fox P.L.L.C. will not be considered confidential or privileged, may be disclosed to others, may not receive a response, and do not create an attorney-client relationship with Sterne Kessler.  If you are not already a client of Sterne Kessler, do not include any confidential information in this message.